Cypress Asset Management Inc. TX purchased a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,829 shares of the medical research company's stock, valued at approximately $1,027,000.
Several other institutional investors have also made changes to their positions in the stock. Centricity Wealth Management LLC bought a new stake in Amgen during the fourth quarter worth $25,000. Pinney & Scofield Inc. bought a new stake in Amgen during the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in Amgen during the fourth quarter worth $34,000. Finally, Atala Financial Inc bought a new stake in Amgen during the fourth quarter worth $34,000. 76.50% of the stock is currently owned by institutional investors.
Amgen Stock Up 1.8%
NASDAQ AMGN traded up $5.14 during trading hours on Thursday, hitting $283.54. The company's stock had a trading volume of 2,801,217 shares, compared to its average volume of 2,801,332. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company's 50-day simple moving average is $284.48 and its two-hundred day simple moving average is $285.76. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $152.46 billion, a PE ratio of 37.56, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same quarter last year, the firm earned $3.96 EPS. The company's quarterly revenue was up 9.4% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.36%. Amgen's dividend payout ratio is currently 86.86%.
Analyst Ratings Changes
Several brokerages have recently issued reports on AMGN. Cantor Fitzgerald began coverage on shares of Amgen in a report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price target for the company. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Johnson Rice set a $294.00 price target on shares of Amgen in a report on Wednesday, March 5th. Guggenheim began coverage on shares of Amgen in a report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target for the company. Finally, UBS Group reiterated a "neutral" rating and set a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of "Hold" and a consensus target price of $309.22.
Check Out Our Latest Analysis on Amgen
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
